BOQI Reports Positive Revenue for Q1
Shares in BOQI International Medical Inc. (Nasdaq: BIMI) rose slightly on Tuesday morning after the company reported positive revenue in the first quarter.
The Dalian-headquartered pharmaceutical provider, founded in 2006, said in a statement that revenue in the first quarter reached $426,898, compared with nil revenue in the same period in 2019. Its net loss hit $2.2 million in the three months through March, up 286% year-over-year.
BOQI newly attributed its revenue to the sales of the wholesale medicine and wholesale medical devices segments from newly acquired Guanzan Group. BOQI acquired the distributor of medicines and medical devices on March 18.
BOQI, formerly known as NF Energy Saving Corporation, explained the nil revenue in the first quarter of 2019 was due to the fact that the business operation of NF Group was reclassified as a discontinued operation.
The company was reorganized to focus on the health industry in February last year, transforming from an energy conservation business to its current medical focus under the leadership of its new board chairman Yongquan Bi.
The company reported a loss from the discontinued operation of $374,486 for the three months ended March.
BOQI saw plummeting customer traffic during the lockdown in the country and some medicines were prohibited for sale due to governmental restrictions, the company said in the statement.
"Despite the impact caused by the pandemic, we completed the acquisition of Guanzan as planned," Tiewei Song, the chief executive officer of BOQI, said in the statement.
Additionally, the company announced on March 2 that it has entered a distributorship agreement with a Chongqing pharmacy company to distribute its treatment, Seradase.
Seradase was used by the Wuhan Jinyintan Hospital to help expectoration by reducing sputum viscosity in patients infected with Covid-19.
BOQI spun off its energy business to Yunfei Lu at an aggregate sale price of $10 million. "The divestiture of the energy business aligns with BOQI International Medical's growth strategy and allows us to further strengthen our financial position," Song said in a statement in April.
The company is now exclusively a healthcare product provider, offering a broad range of healthcare products and related services, according to the company's statement.
Going forward, Song said BOQI raised funds in the second quarter will focus on the telemedicine business in the third quarter.
Shares in BOQI were trading at $2.3 per share, up 1% midday Tuesday.
Xinyuan Property Management Arm Completes HK$127.2 Million Follow on Offering
Inflation Is Up – And So Is Gold
More China IPOs Led by VC, PE, Hillhouse Capital
Moderna Soars 8% on Promising Covid-19 Vaccine News
China Finance Stock Triples on Dow Jones Partnership
Sunshine Stock Selection: July 15 –21